According to the FDA, Arexvy reduced the risk of developing RSV-associated LRTD by 82.6% and severe RSV-associated LRTD by 94.1%. After decades of scientific research, the first vaccine for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results